AQUACYS

What this means for you

Not registered yet, but its 20 Feb 2026 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number

99663191

Mark type

Stylized text

Filed

20 Feb 2026

Attorney of record

Christopher D Olszyk, Jr.

Goods and services

• Class 001 — Chemicals: Biologics, namely, antibodies and antibody conjugates for scientific purposes, other than for medical or veterinary purposes; Biologics, namely, antibody conjugates for use in the formation of nanoparticles, for scientific and medical research; Chemical substances for the formation of antibody conjugates for use in scientific and medical research; Diagnostic preparations for scientific and medical research use in the field of antibody conjugates for scientific and medical research; Biologics, namely, antibody conjugate preparations used to incorporate cysteines into an antibody, namely, protein arrays and nucleotide arrays for scientific and medical research; Biologics, namely, antibodies incorporating engineered cysteines for use in conjugating cysteine reactive small and large molecules, resulting in conjugates with improved hydrophilicity, for scientific and medical research; Biologics, namely, antibodies incorporating engineered cysteines for use in conjugating cysteine reactive small and large molecules, for scientific and medical research; Chemical, biochemical and biological reagents for scientific or medical research use
• Class 005 — Pharmaceuticals: Diagnostic preparations, namely, antibodies incorporating engineered cysteines for use in conjugating cysteine reactive small and large molecules, for medical diagnosis and treatment purposes; Diagnostic preparations, namely, antibodies incorporating engineered cysteines for use in conjugating cysteine reactive small and large molecules, resulting in conjugates with improved hydrophilicity, for medical diagnosis and treatment purposes; Diagnostic preparations, namely, antibodies used to incorporate cysteines into an antibody, namely protein arrays, for medical diagnosis and treatment purposes; Delivery agents for antibodies, namely, drug delivery agents in the form of antibody conjugates that facilitate the delivery and action of medical preparations; Diagnostic preparations, namely, antibody conjugates for medical diagnosis and treatment in the fields of cancer, inflammatory disease, infectious disease and neurologic diseases and disorders; Chemical, biological and biochemical preparations for medical and pharmaceutical use, namely, antibody conjugates for medical diagnosis and treatment in the fields of cancer, inflammatory disease, infectious disease and neurologic diseases and disorders; Pharmaceutical preparations, namely antibody conjugates, for use in the diagnosis and treatment of diseases, namely, cancer, inflammatory disease, infectious disease and neurologic diseases and disorders; Diagnostic preparations featuring large and small molecules, namely, reagents, antibody fragments, antibodies, all intended for use in medical diagnosis and disease treatment; Pharmaceutical preparations and diagnostic preparations, namely, antibodies, antibody conjugates and active principles for medical diagnosis and disease treatment of cancer, inflammatory disease, infectious disease and neurologic diseases and disorders.
• Class 042 — Scientific and technological services: Research and development of antibody conjugates; Scientific research for medical purposes in the field of cancer, inflammatory disease, infectious disease and neurologic diseases and disorders; Research and development services in the field of antibodies; Scientific and technological services and research relating thereto, namely, scientific research, analysis and testing in the fields of antibody conjugates; Antibody engineering; Custom design and engineering of antibodies; Research and development of pharmaceuticals for the treatment of cancer, inflammatory disease, infectious disease and neurologic diseases and disorders; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Research, development and establishment of testing specifications and procedures in the fields of cancer, inflammatory disease, infectious disease and neurologic diseases and disorders research, diagnosis and treatment; Providing scientific research information in the fields of cancer, inflammatory disease, infectious disease and neurologic diseases and disorders research, diagnosis and treatment

Owner

• Aarvik Therapeutics, Inc., Hayward, CA, US

Prosecution history

• 10 Sept 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 10 Sept 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 10 Sept 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 12 Jun 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 12 Jun 2026 — NON-FINAL ACTION E-MAILED
• 12 Jun 2026 — NON-FINAL ACTION WRITTEN
• 10 Jun 2026 — ASSIGNED TO EXAMINER
• 22 Feb 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
• 20 Feb 2026 — APPLICATION FILING RECEIPT MAILED
• 20 Feb 2026 — NEW APPLICATION ENTERED